dilazep has been researched along with Glomerulonephritis, IGA in 9 studies
Dilazep: Coronary vasodilator with some antiarrhythmic activity.
dilazep : A member of the class of diazepanes that is 1,4-diazepane substituted by 3-[(3,4,5-trimethoxybenzoyl)oxy]propyl groups at positions 1 and 4. It is a potent adenosine uptake inhibitor that exhibits antiplatelet, antianginal and vasodilator properties.
Glomerulonephritis, IGA: A chronic form of glomerulonephritis characterized by deposits of predominantly IMMUNOGLOBULIN A in the mesangial area (GLOMERULAR MESANGIUM). Deposits of COMPLEMENT C3 and IMMUNOGLOBULIN G are also often found. Clinical features may progress from asymptomatic HEMATURIA to END-STAGE KIDNEY DISEASE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We collected data for 44 IgA nephropathy children treated with multi-drug combination therapy." | 1.48 | Serum IgA/C3 and glomerular C3 staining predict severity of IgA nephropathy. ( Hosoya, M; Kawasaki, Y; Maeda, R; Ohara, S; Suyama, K, 2018) |
| "Some patients with severe immunoglobulin A nephropathy (IgAN) are resistant to multi-drug combination therapy; however, there have been few reports on the risk factors for non-responsiveness to treatment for severe IgAN." | 1.40 | Resistance factors for the treatment of immunoglobulin A nephropathy with diffuse mesangial proliferation. ( Hashimoto, K; Hosoya, M; Kanno, S; Kawasaki, Y; Miyazaki, K; Ono, A; Sato, M; Suyama, K; Suzuki, Y, 2014) |
| "Immunofluorescence study revealed IgA nephropathy." | 1.35 | Behçet's disease complicated by IgA nephropathy with nephrotic syndrome. ( Hashimoto, T; Inayama, Y; Iwatsubo, K; Kihara, M; Kokuho, T; Kuji, T; Oshikawa, J; Tamura, K; Tanaka, K; Toya, Y; Umemura, S; Yabana, M; Yanagi, M; Yoshida, S, 2008) |
| " Group I (early-treatment group, n = 10) was orally treated with 300 mg/kg body weight of this drug from 12 weeks of age until 60 weeks of age, and group II (late-treatment group, n = 10) was also treated with the same dosage of this drug from 20 weeks of age until 60 weeks of age." | 1.31 | Effect of dilazep hydrochlorideon the Im munohistopathology of IgA nephropathy in ddY mice. ( Hayashi, T; Kaneko, S; Shirato, I; Shou, I; Thang, NT; Tomino, Y, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (11.11) | 18.2507 |
| 2000's | 5 (55.56) | 29.6817 |
| 2010's | 3 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kawasaki, Y | 2 |
| Maeda, R | 1 |
| Ohara, S | 1 |
| Suyama, K | 2 |
| Hosoya, M | 2 |
| Miyazaki, K | 1 |
| Kanno, S | 1 |
| Ono, A | 1 |
| Suzuki, Y | 1 |
| Sato, M | 1 |
| Hashimoto, K | 1 |
| Moriyama, T | 1 |
| Iwasaki, C | 1 |
| Tanaka, K | 2 |
| Ochi, A | 1 |
| Shimizu, A | 1 |
| Shiohira, S | 1 |
| Itabashi, M | 1 |
| Takei, T | 1 |
| Uchida, K | 1 |
| Tsuchiya, K | 1 |
| Nitta, K | 1 |
| Taji, Y | 1 |
| Kuwahara, T | 2 |
| Shikata, S | 1 |
| Morimoto, T | 1 |
| Hashimoto, T | 1 |
| Toya, Y | 1 |
| Kihara, M | 1 |
| Yabana, M | 1 |
| Inayama, Y | 1 |
| Iwatsubo, K | 1 |
| Yanagi, M | 1 |
| Oshikawa, J | 1 |
| Kokuho, T | 1 |
| Kuji, T | 1 |
| Yoshida, S | 1 |
| Tamura, K | 1 |
| Umemura, S | 1 |
| Yoshida, H | 1 |
| Kanatsu, K | 1 |
| Muso, E | 1 |
| Sekita, K | 1 |
| Ono, T | 1 |
| Konishi, N | 1 |
| Kanda, C | 1 |
| Minakata, T | 1 |
| Morimoto, K | 1 |
| Ebihara, I | 1 |
| Nakamura, T | 1 |
| Suzuki, S | 1 |
| Ushiyama, C | 1 |
| Shimada, N | 1 |
| Suzaki, M | 1 |
| Koide, H | 1 |
| Hayashi, T | 1 |
| Kaneko, S | 1 |
| Thang, NT | 1 |
| Shou, I | 1 |
| Shirato, I | 1 |
| Tomino, Y | 1 |
| Haramaki, R | 1 |
| Tamaki, K | 1 |
| Fujisawa, M | 1 |
| Ikedo, H | 1 |
| Haramaki, N | 1 |
| Okuda, S | 1 |
1 review available for dilazep and Glomerulonephritis, IGA
| Article | Year |
|---|---|
Meta-analysis of antiplatelet therapy for IgA nephropathy.
Topics: Dilazep; Dipyridamole; Glomerulonephritis, IGA; Humans; Kidney Function Tests; Platelet Aggregation | 2006 |
1 trial available for dilazep and Glomerulonephritis, IGA
| Article | Year |
|---|---|
Steroid therapy and urinary transforming growth factor-beta1 in IgA nephropathy.
Topics: Adolescent; Adult; Dilazep; Female; Glomerulonephritis; Glomerulonephritis, IGA; Humans; Immunohisto | 2001 |
7 other studies available for dilazep and Glomerulonephritis, IGA
| Article | Year |
|---|---|
Serum IgA/C3 and glomerular C3 staining predict severity of IgA nephropathy.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Biopsy; Child; Complement C3; D | 2018 |
Resistance factors for the treatment of immunoglobulin A nephropathy with diffuse mesangial proliferation.
Topics: Age of Onset; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Biopsy; Calgranulin A; Calgra | 2014 |
Effects of combination therapy with renin-angiotensin system inhibitors and eicosapentaenoic acid on IgA nephropathy.
Topics: Adolescent; Adult; Aged; Blood Pressure; Cohort Studies; Dilazep; Drug Therapy, Combination; Eicosap | 2013 |
Behçet's disease complicated by IgA nephropathy with nephrotic syndrome.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Atorvastatin; Behcet Syndrome; Benzimidazoles; Biphen | 2008 |
Effects of an anti-platelet drug (dilazep) in IgA nephropathy: comparison of clinical effects with renal biopsy findings.
Topics: Adult; Biopsy; Dilazep; Female; Glomerulonephritis, IGA; Humans; Immunoglobulins; Kidney; Male; Prot | 1994 |
Effect of dilazep dihydrochloride on plasma P-selectin concentrations in patients with IgA nephropathy.
Topics: Adult; Case-Control Studies; Dilazep; Glomerulonephritis, IGA; Humans; Middle Aged; P-Selectin; Plat | 2000 |
Effect of dilazep hydrochlorideon the Im munohistopathology of IgA nephropathy in ddY mice.
Topics: Animals; Collagen; Dilazep; Female; Fibronectins; Fluorescent Antibody Technique; Glomerular Mesangi | 2000 |